Shares of Gerresheimer jumped sharply on Thursday after the German pharmaceutical packaging group secured a creditor agreement that reduces the immediate risk of financial distress, providing investors with a period of respite.
The stock surged 18.5 to €20.98 by 07:57 GMT.
About 96% of holders of the company’s €870 million promissory notes consented to extend filing deadlines to September 30, 2026. Banking partners have granted parallel extensions, and the company said that key debt-ratio covenants will be waived through the third quarter. Management framed these moves as steps to stabilize near-term liquidity and creditor visibility.
In parallel, Gerresheimer confirmed it had opened a sale process for Centor, its U.S. subsidiary. The company said it had drawn strong interest from a double-digit number of parties and expects a transaction to be completed before year end.
On the reporting front, Gerresheimer said it plans to publish its audited fiscal 2025 annual report in June, with first-quarter 2026 results to follow "shortly after." That timetable gives market participants a clearer sequence for updated financial disclosure in the coming months.
Analysts at Bernstein said their sentiment on the stock is improving "simply because the decisions taken by the current management are the right ones and offer a certain visibility to the creditors which could prevent a bankruptcy." Their note highlighted that management actions and creditor agreements reduce the most acute short-term insolvency risk.
"The journey to margin recovery is long," the analysts wrote, "even if the stock may enjoy a short term relief."
Bernstein also warned that substantial risks remain. They flagged that costs tied to covenant renegotiations could run €10–20 million above the company’s original €100 million estimate, and they noted there is no visibility yet on the full scope of the internal restructuring the company will pursue.
These developments come after an extended period of operational and governance turmoil at Gerresheimer. The company has faced a sharp deterioration in profitability following its 2024 Bormioli acquisition, accounting issues that are under investigation by Germany’s financial regulator BaFin, and a complete management overhaul. Over the past twelve months the stock has lost more than 70% of its value.
For now, the creditor agreement and parallel bank concessions have bought Gerresheimer time and removed the most immediate threat of insolvency. However, the company still faces an extended path to margin recovery, potential additional restructuring and renegotiation costs, and uncertainty around the final shape of internal changes and asset sales.
Summary
Gerresheimer secured broad creditor support to extend promissory note filing deadlines to September 30, 2026, with banks granting similar extensions and covenants waived through Q3. The company has started a sale process for Centor and expects to publish audited FY25 results in June and Q1 2026 results shortly after. Analysts welcomed the steps as reducing imminent bankruptcy risk but flagged elevated costs and an extended recovery process.